Global Diabetic Neuropathic Pain Drug Market Professional Survey Report 2019

Table of Contents

Executive Summary

1 Industry Overview of Diabetic Neuropathic Pain Drug

• 1.1 Definition of Diabetic Neuropathic Pain Drug
• 1.2 Diabetic Neuropathic Pain Drug Segment by Type
  • 1.2.1 Global Diabetic Neuropathic Pain Drug Production Growth Rate Comparison by Types (2014-2025)
  • 1.2.2 AZD-5213
  • 1.2.3 Clonidine Hydrochloride
  • 1.2.4 Duloxetine Hydrochloride DR
  • 1.2.5 E-52862
  • 1.2.6 Filgrastim
  • 1.2.7 GERPOOI
  • 1.2.8 GRC-17536
  • 1.2.9 Others
• 1.3 Diabetic Neuropathic Pain Drug Segment by Applications
  • 1.3.1 Global Diabetic Neuropathic Pain Drug Consumption Comparison by Applications (2014-2025)
  • 1.3.2 Clinic
  • 1.3.3 Hospital
  • 1.3.4 Others
• 1.4 Global Diabetic Neuropathic Pain Drug Overall Market
  • 1.4.1 Global Diabetic Neuropathic Pain Drug Revenue (2014-2025)
  • 1.4.2 Global Diabetic Neuropathic Pain Drug Production (2014-2025)
  • 1.4.3 North America Diabetic Neuropathic Pain Drug Status and Prospect (2014-2025)
  • 1.4.4 Europe Diabetic Neuropathic Pain Drug Status and Prospect (2014-2025)
  • 1.4.5 China Diabetic Neuropathic Pain Drug Status and Prospect (2014-2025)
  • 1.4.6 Japan Diabetic Neuropathic Pain Drug Status and Prospect (2014-2025)
  • 1.4.7 Southeast Asia Diabetic Neuropathic Pain Drug Status and Prospect (2014-2025)
  • 1.4.8 India Diabetic Neuropathic Pain Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis

• 2.1 Raw Material and Suppliers
• 2.2 Manufacturing Cost Structure Analysis of Diabetic Neuropathic Pain Drug
• 2.3 Manufacturing Process Analysis of Diabetic Neuropathic Pain Drug
• 2.4 Industry Chain Structure of Diabetic Neuropathic Pain Drug

3 Development and Manufacturing Plants Analysis of Diabetic Neuropathic Pain Drug

• 3.1 Capacity and Commercial Production Date
• 3.2 Global Diabetic Neuropathic Pain Drug Manufacturing Plants Distribution
• 3.3 Major Manufacturers Technology Source and Market Position of Diabetic Neuropathic Pain Drug
• 3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers

• 4.1 Diabetic Neuropathic Pain Drug Production and Capacity Analysis
• 4.2 Diabetic Neuropathic Pain Drug Revenue Analysis
• 4.3 Diabetic Neuropathic Pain Drug Price Analysis
• 4.4 Market Concentration Degree

5 Diabetic Neuropathic Pain Drug Regional Market Analysis

• 5.1 Diabetic Neuropathic Pain Drug Production by Regions
  • 5.1.1 Global Diabetic Neuropathic Pain Drug Production by Regions
  • 5.1.2 Global Diabetic Neuropathic Pain Drug Revenue by Regions
• 5.2 Diabetic Neuropathic Pain Drug Consumption by Regions
• 5.3 North America Diabetic Neuropathic Pain Drug Market Analysis
  • 5.3.1 North America Diabetic Neuropathic Pain Drug Production
  • 5.3.2 North America Diabetic Neuropathic Pain Drug Revenue
  • 5.3.3 Key Manufacturers in North America
  • 5.3.4 North America Diabetic Neuropathic Pain Drug Import and Export
• 5.4 Europe Diabetic Neuropathic Pain Drug Market Analysis
  • 5.4.1 Europe Diabetic Neuropathic Pain Drug Production
  • 5.4.2 Europe Diabetic Neuropathic Pain Drug Revenue
  • 5.4.3 Key Manufacturers in Europe
  • 5.4.4 Europe Diabetic Neuropathic Pain Drug Import and Export
• 5.5 China Diabetic Neuropathic Pain Drug Market Analysis
  • 5.5.1 China Diabetic Neuropathic Pain Drug Production
  • 5.5.2 China Diabetic Neuropathic Pain Drug Revenue
  • 5.5.3 Key Manufacturers in China
  • 5.5.4 China Diabetic Neuropathic Pain Drug Import and Export
• 5.6 Japan Diabetic Neuropathic Pain Drug Market Analysis
  • 5.6.1 Japan Diabetic Neuropathic Pain Drug Production
  • 5.6.2 Japan Diabetic Neuropathic Pain Drug Revenue
  • 5.6.3 Key Manufacturers in Japan
  • 5.6.4 Japan Diabetic Neuropathic Pain Drug Import and Export
• 5.7 Southeast Asia Diabetic Neuropathic Pain Drug Market Analysis
  • 5.7.1 Southeast Asia Diabetic Neuropathic Pain Drug Production
  • 5.7.2 Southeast Asia Diabetic Neuropathic Pain Drug Revenue
  • 5.7.3 Key Manufacturers in Southeast Asia
  • 5.7.4 Southeast Asia Diabetic Neuropathic Pain Drug Import and Export
• 5.8 India Diabetic Neuropathic Pain Drug Market Analysis
  • 5.8.1 India Diabetic Neuropathic Pain Drug Production
  • 5.8.2 India Diabetic Neuropathic Pain Drug Revenue
  • 5.8.3 Key Manufacturers in India
  • 5.8.4 India Diabetic Neuropathic Pain Drug Import and Export

6 Diabetic Neuropathic Pain Drug Segment Market Analysis (by Type)

• 6.1 Global Diabetic Neuropathic Pain Drug Production by Type
• 6.2 Global Diabetic Neuropathic Pain Drug Revenue by Type
• 6.3 Diabetic Neuropathic Pain Drug Price by Type

7 Diabetic Neuropathic Pain Drug Segment Market Analysis (by Application)

• 7.1 Global Diabetic Neuropathic Pain Drug Consumption by Application
• 7.2 Global Diabetic Neuropathic Pain Drug Consumption Market Share by Application (2014-2019)

8 Diabetic Neuropathic Pain Drug Major Manufacturers Analysis

• 8.1 Astellas Pharma Inc.
  • 8.1.1 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.1.2 Astellas Pharma Inc. Product Introduction, Application and Specification
  • 8.1.3 Astellas Pharma Inc. Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.1.4 Main Business and Markets Served
• 8.2 AstraZeneca Plc
  • 8.2.1 AstraZeneca Plc Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.2.2 AstraZeneca Plc Product Introduction, Application and Specification
  • 8.2.3 AstraZeneca Plc Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.2.4 Main Business and Markets Served
• 8.3 BioDelivery Sciences International, Inc.
  • 8.3.1 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.3.2 BioDelivery Sciences International, Inc. Product Introduction, Application and Specification
  • 8.3.3 BioDelivery Sciences International, Inc. Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.3.4 Main Business and Markets Served
• 8.4 Boehringer Ingelheim GmbH
  • 8.4.1 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.4.2 Boehringer Ingelheim GmbH Product Introduction, Application and Specification
  • 8.4.3 Boehringer Ingelheim GmbH Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.4.4 Main Business and Markets Served
• 8.5 Daiichi Sankyo Company, Limited
  • 8.5.1 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.5.2 Daiichi Sankyo Company, Limited Product Introduction, Application and Specification
  • 8.5.3 Daiichi Sankyo Company, Limited Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.5.4 Main Business and Markets Served
• 8.6 Dong-A Socio Group
  • 8.6.1 Dong-A Socio Group Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.6.2 Dong-A Socio Group Product Introduction, Application and Specification
  • 8.6.3 Dong-A Socio Group Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.6.4 Main Business and Markets Served
• 8.7 Eli Lilly and Company
  • 8.7.1 Eli Lilly and Company Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.7.2 Eli Lilly and Company Product Introduction, Application and Specification
  • 8.7.3 Eli Lilly and Company Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.7.4 Main Business and Markets Served
• 8.8 Glenmark Pharmaceuticals Ltd.
  • 8.8.1 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.8.2 Glenmark Pharmaceuticals Ltd. Product Introduction, Application and Specification
  • 8.8.3 Glenmark Pharmaceuticals Ltd. Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.8.4 Main Business and Markets Served
• 8.9 Hydra Biosciences, Inc.
  • 8.9.1 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.9.2 Hydra Biosciences, Inc. Product Introduction, Application and Specification
  • 8.9.3 Hydra Biosciences, Inc. Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.9.4 Main Business and Markets Served
• 8.10 Immune Pharmaceuticals Inc.
  • 8.10.1 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Production Sites and Area Served
  • 8.10.2 Immune Pharmaceuticals Inc. Product Introduction, Application and Specification
  • 8.10.3 Immune Pharmaceuticals Inc. Diabetic Neuropathic Pain Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
  • 8.10.4 Main Business and Markets Served
• 8.11 Laboratorios Del Dr. Esteve S.A.
• 8.12 Lohocla Research Corporation
• 8.13 Mertiva AB
• 8.14 Novaremed
• 8.15 Pharmaleads
• 8.16 RAPID Pharmaceuticals AG
• 8.17 Relmada Therapeutics, Inc.
• 8.18 Sphaera Pharma Pvt. Ltd.
• 8.19 Theravasc, Inc.

9 Development Trend of Analysis of Diabetic Neuropathic Pain Drug Market

• 9.1 Global Diabetic Neuropathic Pain Drug Market Trend Analysis
  • 9.1.1 Global Diabetic Neuropathic Pain Drug Market Size (Volume and Value) Forecast 2019-2025
• 9.2 Diabetic Neuropathic Pain Drug Regional Market Trend
  • 9.2.1 North America Diabetic Neuropathic Pain Drug Forecast 2019-2025
  • 9.2.2 Europe Diabetic Neuropathic Pain Drug Forecast 2019-2025
  • 9.2.3 China Diabetic Neuropathic Pain Drug Forecast 2019-2025
  • 9.2.4 Japan Diabetic Neuropathic Pain Drug Forecast 2019-2025
  • 9.2.5 Southeast Asia Diabetic Neuropathic Pain Drug Forecast 2019-2025
  • 9.2.6 India Diabetic Neuropathic Pain Drug Forecast 2019-2025
• 9.3 Diabetic Neuropathic Pain Drug Market Trend (Product Type)
• 9.4 Diabetic Neuropathic Pain Drug Market Trend (Application)
• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.3 Diabetic Neuropathic Pain Drug Customers

11 Market Dynamics

• 11.1 Market Trends
• 11.2 Opportunities
• 11.3 Market Drivers
• 11.4 Challenges
• 11.5 Influence Factors

12 Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List